OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
Zhuchen Yu, Fei Xu, Juntao Zou
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 4, pp. 505-517
Open Access | Times Cited: 7
Zhuchen Yu, Fei Xu, Juntao Zou
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 4, pp. 505-517
Open Access | Times Cited: 7
Showing 7 citing articles:
Targeting Metabolic–Redox Nexus to Regulate Drug Resistance: From Mechanism to Tumor Therapy
Yuke Wang, Jingqiu He, Shan Lian, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 828-828
Open Access | Times Cited: 4
Yuke Wang, Jingqiu He, Shan Lian, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 828-828
Open Access | Times Cited: 4
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
Dongliang Bian, Shuyu Ji, Yue Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Dongliang Bian, Shuyu Ji, Yue Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Clinical practice guidelines for perioperative multimodality treatment of non-small cell lung cancer
Wenjie Jiao, Liang Zhao, Jiandong Mei, et al.
Chinese Medical Journal (2025)
Open Access
Wenjie Jiao, Liang Zhao, Jiandong Mei, et al.
Chinese Medical Journal (2025)
Open Access
Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression
Guihong Zhang, Jiao Liu, Sanzhong Li, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Guihong Zhang, Jiao Liu, Sanzhong Li, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Regulation of keratinocyte barrier function and inflammatory response by the EGFR-STAT3 Pathway: Potential therapeutic implications of osimertinib and afatinib
Xin Chen, Xuekun Nie, Xiao-hui Lin, et al.
Cytokine (2024) Vol. 185, pp. 156802-156802
Closed Access | Times Cited: 1
Xin Chen, Xuekun Nie, Xiao-hui Lin, et al.
Cytokine (2024) Vol. 185, pp. 156802-156802
Closed Access | Times Cited: 1
Genome-Wide Methylation Analysis in Two Wild-Type Non-Small Cell Lung Cancer Subgroups with Negative and High PD-L1 Expression
Georg Hutarew, Beate Alinger-Scharinger, Karl Sotlar, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1841-1841
Open Access
Georg Hutarew, Beate Alinger-Scharinger, Karl Sotlar, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1841-1841
Open Access
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study
Jialong Li, Youyu Wang, Ze-Rui Zhao, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 12, pp. 3344-3351
Open Access
Jialong Li, Youyu Wang, Ze-Rui Zhao, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 12, pp. 3344-3351
Open Access
